Nymox Pharmaceutical Corporation (NYMXF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNymox Pharmaceutical Corporation (NYMXF) trades at $0.0002. Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing treatments for aging-related conditions. Their lead drug candidate, Fexapotide Triflutate (NX-1207), targets benign prostatic hyperplasia and low-grade localized prostate cancer. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NYMXF: NYMXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NYMXF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
NYMXF: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Nymox Pharmaceutical Corporation (NYMXF) Healthcare & Pipeline Overview
Nymox Pharmaceutical Corporation, a biopharmaceutical firm, specializes in developing treatments for aging-related conditions, with a primary focus on Fexapotide Triflutate (NX-1207) for benign prostatic hyperplasia and prostate cancer. The company also markets diagnostic products and explores Alzheimer's disease treatments, operating within the competitive biotechnology sector.
What Is the Investment Thesis for NYMXF?
Nymox Pharmaceutical Corporation presents a speculative investment opportunity within the biotechnology sector, primarily driven by the potential success of its lead drug candidate, Fexapotide Triflutate (NX-1207). The drug's progress in clinical trials for BPH and low-grade localized prostate cancer is a key value driver. Positive clinical trial results and subsequent regulatory approvals could significantly increase the company's market capitalization. However, the company's high beta of 8.90 indicates significant volatility. The absence of a dividend further emphasizes the speculative nature of this investment, as returns are solely dependent on capital appreciation. The company's ability to secure partnerships and funding for further research and development is also crucial for its long-term success. Investors should carefully consider the risks associated with clinical trial outcomes, regulatory hurdles, and market competition before investing in NYMXF.
Based on FMP financials and quantitative analysis
NYMXF Key Highlights
Market capitalization of $0.01 billion reflects its small-cap status and potential for high growth but also higher risk.
- Negative P/E ratio of -3.30 indicates the company is currently not profitable, common for development-stage biopharmaceutical companies.
- High beta of 8.90 suggests the stock is significantly more volatile than the overall market.
- Lead drug candidate, Fexapotide Triflutate (NX-1207), is in clinical trials for BPH and low-grade localized prostate cancer, representing a key potential value driver.
- The company also develops and markets NicAlert and TobacAlert, providing some revenue diversification.
Who Are NYMXF's Competitors?
NYMXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALRTF ALR Technologies Inc. | $0.02 | 0.00% | $12.1M | — |
| DVHGF Devonian Health Group Inc. | $5.78 | -17.43% | $16.1M | — |
| HMTXF Hemostemix Inc. | $0.05 | 0.00% | $10.4M | — |
| HOOK HOOKIPA Pharma Inc. | $1.15 | 0.00% | $14.4M | — |
| IMUC EOM Pharmaceuticals Holdings, Inc. | $0.15 | +0.66% | $19.2M | — |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NYMXF's Key Strengths?
Lead drug candidate (NX-1207) in clinical trials.
- Existing diagnostic products generating revenue.
- Focus on unmet medical needs in aging population.
- Experienced management team.
What Are NYMXF's Weaknesses?
Limited financial resources.
- Dependence on success of NX-1207.
- High beta indicating significant volatility.
- Lack of profitability.
What Could Drive NYMXF Stock Higher?
Clinical trial results for Fexapotide Triflutate (NX-1207) in BPH and low-grade localized prostate cancer.
- Potential regulatory submissions for NX-1207 in various markets.
- Development and commercialization of new diagnostic products.
- Progress in preclinical studies for hepatocellular carcinoma.
- Advancement of Alzheimer's disease drug development program.
What Are the Key Risks for NYMXF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Fexapotide Triflutate (NX-1207).
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established pharmaceutical companies.
- Limited financial resources and dependence on external funding.
- Patent expirations and loss of intellectual property protection.
What Are the Growth Opportunities for NYMXF?
- Expansion of Fexapotide Triflutate (NX-1207) indications: Nymox has the opportunity to expand the use of NX-1207 beyond BPH and low-grade localized prostate cancer. Preclinical studies for hepatocellular carcinoma suggest potential in a larger oncology market. Success in these studies and subsequent clinical trials could significantly increase the drug's market potential, addressing a global market projected to reach $25 billion by 2030.
- Strategic partnerships and collaborations: Nymox can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its products to market. The pharmaceutical industry is characterized by frequent collaborations, with deal values often exceeding hundreds of millions of dollars.
- Geographic expansion: Nymox can expand its geographic presence by seeking regulatory approvals and establishing commercial operations in new markets. Emerging markets, such as China and India, offer significant growth potential due to their large populations and increasing healthcare spending. Entering these markets requires navigating local regulatory requirements and establishing distribution channels.
- Development of new diagnostic products: Nymox can leverage its expertise in diagnostic testing to develop and commercialize new products for detecting various health conditions. The market for diagnostic tests is growing rapidly, driven by increasing awareness of preventive healthcare and technological advancements. Focus on areas such as early cancer detection or personalized medicine could provide significant growth opportunities.
- Advancement of Alzheimer's disease program: Nymox is developing drugs for the treatment of Alzheimer's disease, a significant unmet medical need. Success in this area could be transformative for the company. The Alzheimer's disease market is projected to reach $12 billion by 2028, driven by the aging global population and the increasing prevalence of the disease. However, Alzheimer's drug development is notoriously challenging, with a high failure rate.
What Are NYMXF's Competitive Advantages?
- Patented drug formulations and technologies.
- Proprietary diagnostic tests.
- Clinical trial data and regulatory approvals (if obtained).
- Expertise in developing treatments for aging-related conditions.
What Does NYMXF Do?
Founded in 1989 and headquartered in Nassau, Bahamas, Nymox Pharmaceutical Corporation is a biopharmaceutical company dedicated to the research and development of innovative therapies targeting the aging population. The company's primary focus is on addressing unmet medical needs in areas such as benign prostatic hyperplasia (BPH), low-grade localized prostate cancer, and Alzheimer's disease. Nymox's lead drug candidate, Fexapotide Triflutate (NX-1207), is currently undergoing various clinical trials for the treatment of BPH and low-grade localized prostate cancer. Additionally, preclinical studies are underway to explore its potential in treating hepatocellular carcinoma. Beyond pharmaceutical development, Nymox also develops and markets diagnostic products, including NicAlert, a test for detecting tobacco product usage, and TobacAlert, a test for detecting second-hand smoke exposure. These diagnostic tools complement the company's broader focus on health and wellness. Nymox operates internationally, with activities in Canada, the United States, Europe, and other regions. The company's strategy involves a combination of internal research and development efforts, as well as potential partnerships and collaborations to advance its pipeline and expand its market reach. Nymox faces competition from other biotechnology and pharmaceutical companies developing treatments for similar indications. The company's success depends on the successful completion of clinical trials, regulatory approvals, and commercialization of its products.
What Products and Services Does NYMXF Offer?
- Develops pharmaceutical drugs for aging-related conditions.
- Focuses on treatments for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer.
- Conducts clinical trials for its lead drug candidate, Fexapotide Triflutate (NX-1207).
- Develops and markets diagnostic products for detecting tobacco usage and second-hand smoke exposure.
- Engages in preclinical studies for hepatocellular carcinoma.
- Develops drugs for the treatment of Alzheimer's disease.
- Operates internationally, including in Canada, the United States, and Europe.
How Does NYMXF Make Money?
- Develops and patents pharmaceutical products.
- Conducts clinical trials to gain regulatory approval.
- Markets and sells diagnostic products.
- Potentially licenses or partners with other companies for drug commercialization.
What Industry Does NYMXF Operate In?
Nymox Pharmaceutical Corporation operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for BPH and prostate cancer treatments is substantial and growing, driven by the aging global population. Nymox competes with established pharmaceutical companies and other biotechnology firms developing therapies for similar indications. The success of Nymox depends on its ability to differentiate its products, navigate the regulatory landscape, and secure partnerships to support its research and commercialization efforts. The biotechnology industry is subject to significant regulatory oversight, particularly from the FDA in the United States and the EMA in Europe.
Who Are NYMXF's Key Customers?
- Patients with benign prostatic hyperplasia (BPH).
- Patients with low-grade localized prostate cancer.
- Individuals concerned about tobacco usage and second-hand smoke exposure.
- Healthcare providers and institutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
Nymox Pharmaceutical Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Nassau, BS. The company is led by CEO Paul Averback. NYMXF has traded publicly since 1997.
Key Financial Metrics
Return on equity for Nymox Pharmaceutical Corporation stands at 90.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -20.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -35.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Nymox Pharmaceutical Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NYMXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Lead drug candidate (NX-1207) in clinical trials.
- Existing diagnostic products generating revenue.
- Focus on unmet medical needs in aging population.
- Experienced management team.
Bear Case
- Limited financial resources.
- Dependence on success of NX-1207.
- High beta indicating significant volatility.
- Lack of profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NYMXF Latest News
No recent news available for NYMXF.
NYMXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NYMXF.
Price Targets
Wall Street price target analysis for NYMXF.
NYMXF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NYMXF; grades run from A+ (80-100) to F (below 30).
Leadership: Paul Averback
CEO
Paul Averback serves as the Chief Executive Officer of Nymox Pharmaceutical Corporation. Therefore, a comprehensive background profile cannot be constructed. Averback's professional journey.
Track Record: Information regarding Paul Averback's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. Therefore, a detailed assessment of his track record cannot be provided. Further research beyond the provided data would be necessary to evaluate his performance as CEO of Nymox Pharmaceutical Corporation.
NYMXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nymox Pharmaceutical Corporation may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information, price volatility, and illiquidity. These stocks may not be required to adhere to strict reporting standards, increasing the risk of fraud or misrepresentation.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other tier status.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or misrepresentation.
- Limited liquidity and wider bid-ask spreads.
- Less regulatory oversight compared to exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review any legal or regulatory issues facing the company.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 1989.
- Lead drug candidate in clinical trials.
- Develops and markets diagnostic products.
- Focuses on addressing unmet medical needs.
NYMXF Healthcare Stock FAQ
Is NYMXF a good stock?
Stock Expert AI does not rate NYMXF buy, sell or hold. Nymox Pharmaceutical Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about NYMXF stock?
Due to the limited information available and the company's OTC listing, analyst coverage of NYMXF is likely minimal or non-existent. Key valuation metrics, such as price targets and earnings estimates, are unlikely to be readily available.
What are the key factors to evaluate for NYMXF?
Evaluate NYMXF on fundamentals, analyst consensus, and risk factors. The drug's progress in clinical trials for BPH and low-grade localized prostate cancer is a key value driver. Not financial advice.
How frequently does NYMXF data refresh on this page?
NYMXF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NYMXF's recent stock price performance?
Nymox Pharmaceutical Corporation (NYMXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead drug candidate (NX-1207) in clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NYMXF overvalued or undervalued right now?
Nymox Pharmaceutical Corporation (NYMXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of NYMXF?
Yes, most major brokerages offer fractional shares of Nymox Pharmaceutical Corporation (NYMXF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NYMXF's earnings and financial reports?
Nymox Pharmaceutical Corporation (NYMXF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for NYMXF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete.
- OTC market investments carry higher risk.